Search Results

MC# 21-18
A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor), Rifampicin (a CYP3A4 Inducer), and Omeprazole (a Proton Pump Inhibitor) on the Pharmacokinetics of a Single Oral Dose of Adavosertib in Patients with Advanced Solid Tumours (D601HC00006 & Adavosertib

MC# 21-39
A Phase I/IIa Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination with INCMGA00012 and Epacadostat

MC# 14-30
Phase II Study Of Combined Targeted P53 Gene Therapy (SGT-53) Plus Gemcitabine/Nab-Paclitaxel For Treatment Of Metastatic Pancreatic Cancer

MC# 19-16
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients with Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment

MC# 19-32
A Phase I Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy

MC# 20-03
A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung

MC# 20-24
A Multi-Center, Open-Label, Phase II Study to Evaluate Safety and Efficacy of U3-1402 in Subjects with Advanced or Metastatic Colorectal Cancer (CRC)

MC# 20-36
A Phase I, Open Label, Crossover Study to Establish Bioequivalence Between the Proposed Soft Gel Talazoparib Capsule Formulation and the Current Talazoparib Commercial Formulation and to Estimate the Food Effect on Pharmacokinetics of the Proposed Talazoparib Soft Gel Capsule Formulation in Participants with Advanced Solid Tumors

MC# 20-37
Phase II, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations and Progressed On or After Kinase Inhibitor Therapy and Platinum-based Chemotherapy

MC# 21-09
A Phase I/II, Open-Label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients with Metastatic Castration Resistant Prostate Cancer

MC# 21-13
A Phase II Study of the Hepcidin Mimetic PTG-300 in Patients With Phlebotomy-Requiring Polycythemia Vera

MC# 21-16
A Phase II Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor

MC# 21-22
A Phase I/II randomized, double-blind, placebo-controlled trial examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer

MC# 21-28
A Phase I/II Dose Escalation and Dose Expansion Study of BA3011 Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors

MC# 21-35
A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients with Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients with KRAS-Mutated Non Small Cell Lung Cancer

MC# 21-38
Multicenter, randomized, parallel group, phase II study to establish the efficacy and safety of combinations of CBP501, cisplatin, and nivolumab for ≥3rd line treatment of patients with exocrine pancreatic cancer and WBC

MC# 17-24
A Phase I Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patients with Advanced/Metastatic Solid Tumors or Lymphomas

MC# 18-22
A Phase I/II Study to Investigate the Safety, Pharmacokinetics and Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients with Advanced Solid Tumors. Sub-study to Characterize the Effects of Tinostamustine at a Dose of 60 mg/m2 Administered during a 60-minute Infusion on Cardiac Repolarization in 6 Patients with Advanced Solid Tumors.

MC# 19-25
A Phase I open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors

MC# 19-27
A Phase I Study of AGEN2373, an Anti-CD137 Monoclonal Antibody in Subjects with Advanced Cancer

MC# 20-08
An Open-label, Dose Escalation, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors

MC# 20-16
An Open-Label, Multicenter, Phase IB/II Study to Establish Safety, Tolerability, and Optimal Dosing Strategy of GLR2007 in Subjects with Advanced Solid Tumors

MC# 20-17
A Phase I, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of T3011 in Advanced Cutaneous or Subcutaneous Malignancies

MC# 20-18
An Open-Label, Multicenter, Phase II Basket Study to Evaluate the Efficacy and Safety of Lenvatinib (14 mg/m2) in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies (Pediatric Solid Tumor Basket Trial)

MC# 20-23
An Open-Label, Multicenter Phase I/II Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects with Advanced or Metastatic Solid Tumors